Updates Regarding Radiation Necrosis

Radiation necrosis—a delayed, inflammatory brain injury following radiation therapy—remains a clinical puzzle due to its unpredictable course and difficulty distinguishing it from tumor recurrence on MRI. Kate Neville, a neuro-oncologist at Indiana University, explains that while radiation necrosis typically emerges 1–2 years post-treatment (though it can appear up to a decade later), its hallmark is vascular endothelial damage and coagulative necrosis, often presenting with headaches, seizures, or focal deficits. The key diagnostic challenge lies in differentiating it from tumor progression, where perfusion MRI showing low cerebral blood volume (CBV) favors necrosis, while high CBV suggests tumor. Advanced tools like amino acid PET and clinical context—such as symptom presence in high-impact brain regions—add critical clues. For symptomatic cases, dexamethasone remains first-line due to rapid availability and lower procedural burden than bevacizumab, though both carry significant toxicity. Crucially, Neville advocates for early use of MRI with perfusion in any post-radiation patient with new neurological symptoms. Beyond conventional treatments, she highlights boswellia (Indian frankincense) as a promising, well-tolerated supplement with retrospective evidence showing a 6-month average response time in reducing cerebral edema—offering a potential long-term, low-risk alternative to steroids and bevacizumab, especially in asymptomatic or transitioning patients. The episode reframes radiation necrosis not as an inevitable complication but as a manageable condition where early imaging, strategic treatment sequencing, and off-label supplements like boswellia can shift the clinical trajectory. Neville’s pragmatic approach—using boswellia proactively in asymptomatic patients at risk of symptom onset or as a tapering bridge after steroids—challenges the status quo of relying solely on toxic agents. This represents a significant shift toward preventive, patient-centered care in neuro-oncology, where the goal is not just to treat symptoms but to avoid the cumulative burden of treatment side effects.